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Introduction	Type	1	diabetes	is	an	autoimmune	disease	characterized	by	the	destruction	of	 insulin-producing	pancreatic	beta	cells.	This	condition	reduces	life	expectancy	by	up	to	fifteen	years	and	leads	to	significant	health	care	expenses	[1].	In	2015,	the	global	estimates	of	the	number	of	children	living	with	type	1	diabetes	exceeded	half	a	million,	and	some	86,000	new	cases	are	estimated	to	occur	annually	[2].			 Currently,	a	promising	treatment	for	type	1	diabetes	is	pancreatic	islet	transplantation.	The	loss	of	rich	vascular	network	by	native	islets	during	isolation	from	donors,	however,	results	in	the	low	survival	of	large	 islets	 post-transplantation.	 A	 promising	 proposal	 is	 to	 disperse	 native	 islets	 into	 single-cell	suspensions	 and	 aggregate	 them	 into	 smaller,	 uniform	 “pseudo-islets”.	 The	 recovery	 of	 cell	mass	 after	dissociation	still	remains	a	major	challenge	that	limits	the	yield	and	efficacy	of	pseudo-islet	aggregations	[3].	As	such,	the	objective	of	this	study	is	to	determine	the	optimal	dissociation	protocol	for	the	formation	of	human	pseudo-islets.	We	hypothesized	that	by	enhancing	the	dissociation	protocol	for	native	human	islets,	more	cells	can	be	recovered	and	they	will	form	pseudo-islets	that	function	more	effectively	in	terms	of	insulin	secretion	and	survivability.			
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Methods	A	 literature	 review	 was	 conducted	 to	determine	 the	 reagents	 previously	 used	 to	dissociate	 native	 islets.	 Using	 the	 search	 engine	PubMed,	 we	 searched	 the	 MEDLINE	 database	(1980	to	May	2016)	to	determine	the	dissociation	reagents,	 concentrations,	 and	 time	 outlined	 in	literature.	All	trials	outlining	the	methods	used	to	dissociate	native	rat,	mouse,	hamster,	or	human	islets	were	included.		Each	of	 the	3	native	post-mortem	human	islet	samples	(1	 female	and	2	male;	ages	41,	56,	and	 75;	 all	 negative	 for	 HIV,	 HCV,	 HBV	 testing;	isolated	and	supplied	by	Clinical	Islet	Laboratory	at	University	of	Alberta)	were	centrifuged	at	120	x	 g	 for	 1	minute	 in	 50	mL	 centrifuge	 tubes	 and	after	 removing	 the	 supernatant,	 resuspended	 in	CMRL-1066	 media	 (containing	 amino	 acids,	vitamins,	 and	 other	 components).	 The	 samples	were	 further	 divided	 into	 several	 tubes	 and	centrifuged	at	120	x	g	for	1	minute.	Two	thousand	islet	 equivalents	 (islets	 with	 a	 diameter	 of	 150	μm)	per	1	mL	of	dissociation	reagents	(Accutase,	Accumax,	 TrypLE	 Express,	 0.05%	 Trypsin	 in	phosphate-buffered	saline	(PBS),	0.05%	Trypsin	with	0.02%	Versene	(EDTA)	in	PBS,	and	Dispase	in	PBS	ranging	from	2	–	5	U/mL)	were	added	with	0.0015%	DNase	into	each	of	the	tubes.	Accumax	contains	the	same	proteolytic	and	collagenolytic	enzymes	 as	 Accutase,	 but	 is	 three	 times	 more	concentrated.	 Trypsin	 is	 a	 pancreatic	 serine	protease,	while	TrypLE	Express	is	a	recombinant	enzyme.	Dispase	contains	neutral	protease	 from	
Bacillus	polymyxa.	During	the	dissociation	period,	tubes	with	Accutase	or	Accumax	were	left	at	room	temperature	due	to	their	sensitivity	to	heat	while	the	rest	of	the	tubes	were	put	into	a	37	°C	shaking	water	bath	to	speed	up	the	dissociation	process.	Subsequently,	 the	 cells	 were	 mechanically	dissociated	 into	 single-cell	 suspensions	 by	trituration.	After	11-15	minutes,	 the	 tubes	were	topped	up	with	CMRL	media	to	5	mL	in	order	to	stop	the	dissociation	process.		The	 cells	were	 centrifuged	 at	 280	 x	 g	 for	 1	minute	 and	 resuspended	 in	 5	 mL	 of	 CMRL.	Samples	 were	 collected	 from	 the	 tubes	 for	 cell	counting	(pre-filtering	viability/	cell	counts),	and	
the	remaining	were	filtered	using	cell	strainers	to	obtain	uniform	cell	 suspensions.	After	 filtration,	cell	counting	samples	were	obtained	again	(post-filtering	 viability/	 cell	 counts).	 Samples	 were	analyzed	using	Trypan	Blue	and	PicoGreen	DNA	assay	to	quantify	cell	loss	during	islet	dispersion	and	 filtration.	 The	 cell	 suspensions	were	 added	into	24-well	AggreWell	plates	with	CMRL	in	them	and	centrifuged	at	200	x	g	for	5	minutes	to	form	smaller,	uniform	pseudo-islets.	The	pseudo-islets	were	 cultured	 in	 microwells	 in	 a	 cell	 culture	incubator	(37	°C,	5%	carbon	dioxide)	up	to	5	days	(5	 day	 cell	 viability/	 cell	 counts).	 During	 the	culture	 period,	 samples	 for	 cell	 counting	 were	collected	 and	 assessed	 using	 PicoGreen	 DNA	assay	while	the	metabolic	activity	of	pseudo-islets	was	assessed	using	Alamar	Blue	assay.	Statistical	analysis	were	performed	with	one-way	ANOVA.				
Results	Twenty	studies	met	the	inclusion	criteria,	from	 which	 we	 identified	 the	 dissociation	reagents,	 concentrations,	 and	 time	 previously	used	 to	 dissociate	 native	 islets	 [3-22].	 These	studies	 employed	 Trypsin,	 TrypLE,	 Accutase,	Dispase,	 and	 Papain	 to	 dissociate	 native	 islets	with	 Trypsin	 being	 the	 most	 common.		Dissociation	times	ranged	from	3	to	15	minutes.	In	 our	 experiments	 comparing	 the	 dissociation	reagents,	TrypLE	showed	the	highest	percentage	of	recovered	viable	cells	after	filtration	(85	±	43),	followed	 by	 Accumax	 (56	 ±	 22),	 Trypsin	 with	EDTA	(49	±	5),	Accutase	(25	±	2),	Dispase	5	U/mL	(11),	and	Dispase	3	U/mL	(8).	Cell	survival	during	the	culture	period	was	found	to	vary	between	the	trials	 which	 may	 be	 due	 to	 the	 inherent	differences	 between	 donor	materials	 (Accumax:	65	±	19%,	Trypsin	with	EDTA:	64	±	31%,	TrypLE:	57	±	8%,	Accutase:	48%,	Dispase	3	U/mL:	59%,	Dispase	5	U/mL:	57%).		Overall,	 TrypLE	 ranked	 the	 highest	 in	terms	 of	 the	 recovery	 coefficient,	 followed	 by	Accumax	and	Trypsin	with	EDTA	(Table	1).	The	recovery	coefficient	takes	total	cells	present	post-filtration,	%	viable	cells	 in	suspension,	and	cells	remaining	 post-culture	 into	 consideration.	Metabolic	 activity	 per	 cell	 remaining	 was	 not	
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included	 as	 the	 implications	 are	 currently	unclear.		Table	1	shows	the	recovery	coefficients	±	SD,	assessed	 using	 total	 number	 of	 cells	 recovered,	percentage	of	viable	cells	in	suspensions,	and	cell	survival	 post-culture,	 with	 equation	 1	representing	how	this	was	calculated.	
	
	
Table	1.	Ranking	of	the	dissociation	reagents.	
	
Discussion	&	Conclusion	Due	to	 the	 limited	supply	of	donor	 islets,	only	 3	 trials	 with	 different	 native	 islet	 samples	were	 conducted	during	 the	 study	period.	 In	 the	future,	 trials	 will	 be	 replicated	 to	 increase	 the	reliability	of	the	study.	To	determine	the	optimal	timing	for	TrypLE	and	Accumax,	the	dissociation	times	 of	 these	 most	 promising	 dissociation	reagents	 will	 also	 be	 varied.	 Results	 from	 the	study	 are	 promising	 and	 further	 investigations	will	 allow	 the	 results	 to	 become	 applicable	 to	clinical	trials,	which	can	directly	help	increase	the	number	 of	 treatable	 patients	 from	 the	 limited	supply	of	donor	islets.	
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